🎓 ¡Enhorabuena al Dr. Miguel Mansilla Polo por la defensa de su tesis!
💫 Se trata de una investigación, dirigida por los Dres. Rafael Botella y Jaime Sanz, sobre cáncer cutáneo en receptores de TPH que impulsa el avance en dermatología tras el trasplante.
Another one! What an incredible year it’s been! Huge congrats to Juan on the EBMT study collaboration on HSCT in ALL. Now for a well-deserved summer break!@ @IISLaFe@Mohty_EBMT@TheEBMT@GETH_info@HospitalLaFe
https://t.co/ygHZZlOiNk
Another one accepted! The team's on an incredible streak — what a year we're having! Engraftment Syndrome after Post-Transplant Cyclophosphamide Allogeneic Hematopoietic Cell Transplantatio… https://t.co/rzL0o4M7oD @TheEBMT@GETH_info@IISLaFe@HospitalLaFe
Another one! Big congrats to Aitana! Our team's scientific production is unstoppable! Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosp… https://t.co/M6xALn7skJ @GETH_info@TheEBMT@IISLaFe@HospitalLaFe
A new manuscript in collaboration with the EBMT. This time about aplastic anemia. What a productive year it's been for the Unit. Donor impact on allo-SCT outcomes with PTCy for SAA: a study of the SAAWP EBMT https://t.co/q1nQjtfsC6 @GETH_info@HospitalLaFe@TheEBMT@IISLaFe
Congratulations to the team on the new manuscript! We continue to push forward—great work Pedro!! Infectious Enterocolitis in Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide https://t.co/wXUbFrQnWe @GETH_info@GVAsanitat@IISLaFe@HospitalLaFe@TheEBMT
Another manuscript! This from our colleague from Chile, who chose to stay with the team not just to learn, but to actively drive impactful research. CRS syndrome: implications for transplant outcomes in haplo and HLA-matched HSCT using PTCy https://t.co/qbXrSOXWeR @TheEBMT
📊 Memoria TPH 2024 publicada
❤️ 101 pacientes alotrasplantados
Un año más, seguimos como el centro nacional con mayor actividad en alo-TPH.
Gracias a todos los que lo hacéis posible. Enhorabuena, equipo. @GVAsanitat@HospitalLaFe@GETH_info@TheEBMT@IISLaFe@ONT_esp@fcarreras
T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy https://t.co/FjXme7rKaK
Severe (Grade 3+) T-ICAHT is strongly associated with increased transfusion burden and inferior survival following CAR T-cell therapy.
🏥La Fe formaliza la creación de un comité multidisciplinar para el abordaje de la enfermedad de #injerto contra receptor
‼️Es una complicación inmunológica, multiorgánica y potencialmente mortal
🔗https://t.co/fPaJS2yznf
This #EBMT25 our group is on fire!! Four oral communications (including Juan Montoro at the Presidential Symposium), two posters. Well done! 👏👏@HospitalLaFe@GETH_info#SCT